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Figure 1 CKD prevalence illustrated using KDIGO’s eGFR / albuminuria grid1 
(adaptation of data from Hill et al.)2 
 
 
   Albuminuria Categories  
(mg/g creatinine) 
   A1 A2 A3 
   < 30 30-300 > 300 
GFR Categories 
(mL/min x 1.73 m2) 
G1 > 90  3.5 (2.8-4.2) % 
G2 60-89  3.9 (2.7-5.3) % 
G3a 45-59 
7.6 (6.4-8.9) % 
G3b 30-44 
G4 15-29 0.4 (0.3-0.5) % 
G5 < 15 0.1 (0.1-0.1) % 
 
 
Figure 2 Heatmap of risk of AKI as a function of pre-existing eGFR and 
albuminuria in diabetics and non-diabetics3 
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Figure 3 Number of associated genes/loci for monogenic and complex kidney 
diseases and their overlap (adaptation of figure from Wuttke)4 
 
 
 
 
Target Therapy Status/Results 
Trial  
Registration # 
Diabetic 
Nephropathy 
Aliskiren (ALTITUDE) Phase 3 study terminated due to harm5 NCT00549757 
Anti-connective tissue 
growth factor (CTGF) 
antibody FG-3019 
Phase 2 study terminated due to 
suboptimal design 
NCT00913393 
Anti-transforming 
growth factor-beta 
(TGF-β) kinase 
antibody (LY2382770) 
Phase 2 study terminated due to lack of 
efficacy 
NCT01113801 
Bardoxolone Methyl 
Phase 3 study terminated due to safety 
concerns 
NCT01351675 
C-C chemokine 
receptor type 2 
(CCR2) antagonism 
Phase 2 study completed6 NCT01447147 
Endothelin-A 
antagonist Atrasentan 
Phase 3 study currently recruiting NCT01858532 
Mineralocorticoid 
antagonist 
Phase 2 study completed7 NCT01874431 
Nox1/4 inhibitor 
(Oral GKT137831) 
Phase 2 study completed: negative results  NCT02010242 
Phosphodiesterase 5 
inhibitor 
Phase 2 study completed8 NCT01200394 
Pirfenidone 
Phase 1, 2 study completed: results not 
reported 
NCT02408744 
Pyridorin 
Phase 3 study terminated due to lack of 
funding 
NCT02156843 
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Target Therapy Status/Results 
Trial  
Registration # 
IgA 
Nephropathy 
Blisibimod Phase 2, 3 study active but not recruiting NCT02062684 
Bortezomib Phase 4 study recruiting  NCT01103778 
Combination 
immuosuppression  
(STOP IgA)  
Phase 3 study completed: negative results 
and a signal for harm9 
NCT00554502 
Fostamatinib Phase 2 study recruiting NCT02112838 
Nefecon  
Phase 2 study completed: reported 
positive outcomes 
NCT01738035 
Rituximab Phase 4 study recruiting  NCT02571842 
Rituximab Phase 4 study completed  NCT00498368 
Steroids in IgA 
nephropathy 
(TESTING) 
Study active but not recruiting, modified 
due to harm signal 
NCT01560052 
Proteinuric 
CKD 
Curcumin 
Phase 3 study completed: results not 
reported 
NCT01831193 
LCZ696 (UK HARP-III) Study active but not recruiting ISRCTN11958993 
Adult PKD 
Octreotide LAR  
(ALADIN 2) 
Phase 3 study active but not recruiting NCT01377246 
Octreotide LAR 
(ALADIN) 
Phase 3 study competed10 NCT00309283 
Sirolimus  
Phase 2,3 study terminated due to safety 
and efficacy concerns11 
NCT01223755 
Tolvaptan 
Phase 3 study active but not recruiting in 
patients with CKD Stage 2-4  
NCT02160145 
Tolvaptan  
(TEMPO 3/4) 
Phase 3 study completed12,13  NCT00428948 
Water loading 
Observational study completed: results not 
yet reported 
NCT01348035 
Lupus 
Nephritis 
Abatacept 
Phase 2 study completed: negative 
results14 
NCT00774852 
Phase 3 study active but not recruiting  NCT01714817 
Atacicept 
Phase 2, 3 study terminated due to safety 
issues 
NCT00573157 
Belimumab Phase 3 study recruiting NCT01639339 
Blisibimod Phase 3 study recruiting  NCT02514967 
Etanercept 
Phase 2 study terminated: perceived risk-
benefit ratio for individuals with early 
active RA 
NCT00447265 
Infliximab 
Phase 2,3 study terminated due to failure 
to recruit 
NCT00368264 
Rituximab 
Phase 3 study completed: negative 
results15 
NCT00282347 
Phase 3 study recruiting (as a single agent 
+ standard of care) 
NCT01673295 
Phase 2 study recruiting  
(in combination with Belimumab) 
NCT02260934 
Phase 3 study recruiting (in combination 
with Mycophenolate Mofetil) 
NCT01773616 
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Target Therapy Status/Results 
Trial  
Registration # 
Anti-Neutrophil 
Cytoplasmic 
Antibody 
(ANCA) 
vasculitis 
Alemtuzumab Phase 4 study, status unknown NCT01405807 
Eculizumab  
Phase 2 study terminated due to failure of 
patient enrolment  
NCT01275287 
Miscellaneous 
Eculizumab in C3 GN 
and dense deposit 
disease  
Phase 1 study, status unknown NCT01221181 
Rituximab in relapsing 
idiopathic nephrotic 
syndrome 
Phase 3 study completed16 NCT00981838 
Table 1 Recent Therapeutic Trials for CKD 
 
 
Figure 4 Timeline of translation from SNP discovery to clinical application 
(adaptation of figure from Fox).17 Translation of genetic findings from their discovery to 
insights into the underlying molecular mechanisms and to clinical application can take 
decades and is associated with high costs 
 
 
  
5 
Web Appendix files – Manuscript: THELANCET-D-16-07352 
 
Figure 5 Geospatial risk analysis for IgA nephropathy (figure from Kiryluk)18 based 
on the distribution of a standardized genetic risk score from populations sampled 
around the World 
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